

November 2, 2022



REIG JOFRE'S JOINT VENTURE, **SYNA THERAPEUTICS**, SIGNS WITH INTAS PHARMACEUTICALS Ltd. A GLOBAL LICENSE AGREEMENT FOR ITS BIOSIMILAR LB-0702

Barcelona (Spain), REIG JOFRE, (BME:**RJF**) pharmaceutical company listed on the Spanish stock exchange established in 2018 the *joint-venture* **Syna Therapeutics**, 50% owned by LeanBio and REIG JOFRE, for the development of biopharmaceutical products in the field of biosimilars and innovative molecules. After 4 years, Syna Therapeutics has just signed an exclusive license agreement with Intas Pharmaceuticals Ltd. ("Intas") and its wholly owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702.

According to the terms of the agreement, Syna Therapeutics will begin in 2023 the clinical trials for its biosimilar LB-07802 to treat pathologies in the field of hematology. For its part, Intas Pharmaceutical Ltd., a global biopharmaceutical company, will cover the marketing costs. Intas currently has one of the largest sales, marketing, and distribution networks for biosimilars in the world, particularly to hospitals, with a presence in 85 countries.

REIG JOFRE will contribute to the development and stabilization of the final pharmaceutical product, besides offering its first-rate global production capacity in its new development and specialized production center in Barcelona, which after an investment of €40 million completed in 2021, has state-of-the-art technology and the highest quality standards for sterile injectables and lyophilized biopharmaceutical products, with an annual capacity of up to 45 million lyophilized aseptic vials and 50 million liquid solution vials.

REIG JOFRE thus contributes to a greater integration of the biological drug development and manufacturing process, uniting through Syna Therapeutics the development of the active ingredient and the production of the final biopharmaceutical product.

Patient access to innovative treatments worldwide

A biosimilar (or similar biological medicine) is a biological medicine equivalent in quality, efficacy, and safety to an original biological medicine, called a reference product. Biosimilars are characterized by being large molecules with greater structural complexity than chemically synthesized drugs, which makes them very sensitive to changes in the manufacturing process.

Further information

Inma Santa-Pau - Director of Communication and Investor Relations - isantapau@reigjofre.com

www.reigjofre.com



In recent decades, biotechnological medicines have played an increasingly important role in health care and treatment. In this sense, and despite the complexity of the technology required for the development of off-patent biologicals and the costly manufacturing processes, it is expected that in the coming years the development of biosimilars will be a significant area of growth to deliver biotech products more effectively to worldwide patients, either by being able to offer more sustainable prices in markets where the original biological product exists, or by being able to give access to innovative treatments to world markets in which the therapy is not available.

REIG JOFRE, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements, structures its activity into three business units: (1) *Pharmaceutical Technologies* specialized in sterile injectables, lyophilized products and beta-lactam antibiotics; (2) *Specialty Pharmacare* in dermatology and osteoarticular, mainly; and (3) *Consumer Healthcare* with food supplements aimed at consumers under the Forté Pharma brand, mainly in France, Belgium, Spain and Portugal, and OTC products. Founded in 1929 in Barcelona (Spain), REIG JOFRE has more than 1,100 employees, 4 development and production centers in Europe, subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore) and 155 commercial partners in more than 70 countries. In 2021, the company's turnover was €236 million.